Search results
Results from the WOW.Com Content Network
Number of employees. 407 (2023) ... Massachusetts, San Francisco, California and London, United Kingdom. ... CRISPR Therapeutics was founded in 2013 by Emmanuelle ...
The U.K. had already approved the CRISPR treatment, called exa-cel (brand name: Casgevy), from Vertex Pharmaceuticals and CRISPR Therapeutics (which was co-founded by Charpentier), to treat people ...
CRISPR Therapeutics recently hit a breakthrough point when it earned approval for its first product, Casgevy, a therapy for sickle cell disease and transfusion-dependent beta-thalassemia.
CRISPR Therapeutics has a $3.9 billion market cap at recent prices, but the stock is less expensive than it looks on the surface. With a big cash cushion and a lack of debt, its enterprise value ...
CasPEDIA — a wiki-style database of the known CRISPR-associated (Cas) proteins, their activity and use cases, launched in 2023 by a group of researchers at the IGI. [71] CRISPR Clinical Trials — an annual summary of CRISPR-based therapies currently in clinical trials, broken down by disease area. [72]
CRISPR Therapeutics has two next generation approaches with the potential to significantly expand the addressable population with SCD and TDT. The Company continues to advance its internally developed targeted conditioning program, an anti-CD117 (c-Kit) antibody-drug conjugate (ADC), through preclinical studies.
For premium support please call: 800-290-4726 more ways to reach us
About CRISPR Therapeutics Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company that celebrated the historic approval of the first-ever CRISPR-based therapy in 2023 and has a diverse portfolio of product candidates across a broad ...